Wednesday, August 31, 2022
12:20 PM EST – Pharmala Biotech Holdings Inc : Have been selected as the MDMA manufacturing partner for the University of Sydney’s upcoming Phase 2 Clinical Trial. Founded in 1850, The University of Sydney is one of the top universities in Australia. There is a high rate of comorbidity between alcohol use disorders and Post Traumatic Stress Disorder which is associated with greater clinical impairment and poorer prognosis. Led by Dr. Kirsten Morley, Principal Investigator, the trial will examine whether MDMA can enhance outcomes for patients with these treatment resistant complexities. Pharmala Biotech Holdings Inc (C.MDMA) shares were down one cent at 0.05.
Stocks in Play: Pharmala Biotech Holdings Inc, Wed, 31 Aug 2022 12:27:08 EST